Literature DB >> 31765766

Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: A systematic review and meta-analysis.

Ali Pormohammad1, Kobra Mehdinejadiani2, Pourya Gholizadeh3, Mohammad Javad Nasiri4, Naser Mohtavinejad5, Masoud Dadashi6, Samira Karimaei7, Hossein Safari8, Taher Azimi9.   

Abstract

INTRODUCTION: Acinetobacter baumannii antimicrobial resistance is a public health concern in developing and developed countries, especially in the hospital setting. Understanding the antibiotic resistance profile can help to provide better guidelines for the prescription of appropriate antibiotics, reduction of antibiotic resistance, and introducing new and effective treatment options.
METHOD: Using the PRISMA guidelines, databases of PubMed, Embase, and Cochrane Library were searched systematically from January 1, 2000, to January 1, 2018. All statistical analyses were carried out via Comprehensive Meta-Analysis Software Version 2.0 (Biostat, Englewood, NJ). Depending on the heterogeneity test, either random or fix effect models were used for determining the pooled prevalence of drug resistance. RESULT: A total of 150 studies were included from 41 countries of six different WHO regional offices worldwide. The highest and the lowest rate of resistance were observed for cefotaxime (99%, 95% CI: 95-99.9) in Africa and colistin (1.1%, 95% CI: 0.3-4.5) in Western Pacific, respectively. Lebanon (17.5%, 95% CI: 16-19) and China (12%, 95% CI: 3.5-32.5) had the highest and Germany (0.2%, 95% CI: 0-2.5) had the lowest rate of resistance for colistin.
CONCLUSION: Our analysis showed that prevalence and rate of increased colistin resistance in South-East Asia and Eastern Mediterranean countries are higher than other regions of the world. Therefore, the establishment of appropriate antibiotic usage guidelines should be essential in these countries.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Acinetobacter baumanni; Drug resistance; Meta-analysis; Prevalence

Mesh:

Substances:

Year:  2019        PMID: 31765766     DOI: 10.1016/j.micpath.2019.103887

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  20 in total

1.  Acinetobacter baumannii Genomic Sequence-Based Core Genome Multilocus Sequence Typing Using Ridom SeqSphere+ and Antimicrobial Susceptibility Prediction in ARESdb.

Authors:  Madiha Fida; Scott A Cunningham; Stephan Beisken; Andreas E Posch; Nicholas Chia; Patricio R Jeraldo; Matthew P Murphy; Nicole M Zinsmaster; Robin Patel
Journal:  J Clin Microbiol       Date:  2022-07-12       Impact factor: 11.677

2.  Epidemiological and genetic characteristics of clinical carbapenem-resistant Acinetobacter baumannii strains collected countrywide from hospital intensive care units (ICUs) in China.

Authors:  Congcong Liu; Kaichao Chen; Yuchen Wu; Ling Huang; Yinfei Fang; Jiayue Lu; Yu Zeng; Miaomiao Xie; Edward Wai Chi Chan; Sheng Chen; Rong Zhang
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

3.  Performance Evaluation of the VITEK2 and Sensititre Systems to Determine Colistin Resistance and MIC for Acinetobacter baumannii.

Authors:  Hae-Sun Chung; Soo-Kyung Kim; Chorong Hahm; Miae Lee
Journal:  Diagnostics (Basel)       Date:  2022-06-17

4.  In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era.

Authors:  Priya Sreenivasan; Bhawna Sharma; Satinder Kaur; Sudesh Rana; Manisha Biswal; Pallab Ray; Archana Angrup
Journal:  J Antibiot (Tokyo)       Date:  2022-06-17       Impact factor: 3.424

5.  Whole-Genome Sequencing of a Colistin-Resistant Acinetobacter baumannii Strain Isolated at a Tertiary Health Facility in Pretoria, South Africa.

Authors:  Noel-David Nogbou; Mbudzeni Ramashia; Granny Marumo Nkawane; Mushal Allam; Chikwelu Lawrence Obi; Andrew Munyalo Musyoki
Journal:  Antibiotics (Basel)       Date:  2022-04-28

6.  Isolation and Characterisation of Bacteriophage Selective for Key Acinetobacter baumannii Capsule Chemotypes.

Authors:  Rosesathorn Soontarach; Potjanee Srimanote; Mark C Enright; George Blundell-Hunter; Matthew J Dorman; Nicholas R Thomson; Peter W Taylor; Supayang P Voravuthikunchai
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-02

7.  Colistin heteroresistance in carbapenem-resistant Acinetobacter baumannii clinical isolates from a Thai university hospital.

Authors:  Khin Thet Thet; Kamonwan Lunha; Arpasiri Srisrattakarn; Aroonlug Lulitanond; Ratree Tavichakorntrakool; Waewta Kuwatjanakul; Nicha Charoensri; Aroonwadee Chanawong
Journal:  World J Microbiol Biotechnol       Date:  2020-07-01       Impact factor: 3.312

8.  Prevalence and Characterization of Carbapenem-Hydrolyzing Class D β-Lactamase-Producing Acinetobacter Isolates From Ghana.

Authors:  Alafate Ayibieke; Ayumi Kobayashi; Masato Suzuki; Wakana Sato; Samiratu Mahazu; Isaac Prah; Miyuki Mizoguchi; Kyoji Moriya; Takaya Hayashi; Toshihiko Suzuki; Shiroh Iwanaga; Anthony Ablordey; Ryoichi Saito
Journal:  Front Microbiol       Date:  2020-11-13       Impact factor: 5.640

9.  WGS-Based Analysis of Carbapenem-Resistant Acinetobacter baumannii in Vietnam and Molecular Characterization of Antimicrobial Determinants and MLST in Southeast Asia.

Authors:  Gamal Wareth; Jörg Linde; Ngoc H Nguyen; Tuan N M Nguyen; Lisa D Sprague; Mathias W Pletz; Heinrich Neubauer
Journal:  Antibiotics (Basel)       Date:  2021-05-11

10.  Antimicrobial Resistance Mechanisms and Virulence of Colistin- and Carbapenem-Resistant Acinetobacter baumannii Isolated from a Teaching Hospital in Taiwan.

Authors:  Noor Andryan Ilsan; Yuarn-Jang Lee; Shu-Chen Kuo; I-Hui Lee; Tzu-Wen Huang
Journal:  Microorganisms       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.